Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
Diabetes Obes Metab
; 25(5): 1413-1418, 2023 05.
Article
in En
| MEDLINE
| ID: mdl-36655422
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Diabetes Mellitus, Type 2
/
Renal Insufficiency, Chronic
/
Fatty Liver
Limits:
Humans
Language:
En
Journal:
Diabetes Obes Metab
Journal subject:
ENDOCRINOLOGIA
/
METABOLISMO
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: